BRAF and thyroid gland carcinoma: Another retrospective study of dabrafenib plus trametinib combination therapy in BRAF V600E-positive thyroid cancer reported an objective response rate of 73.1% in 27 patients, and the high response rate in that study may have been due to the high proportion of early-stage cases [7].